Company profile
Clinuvel Pharmaceuticals company profile
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing drugs for the treatment of a range of severe skin disorders. Its lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://www.clinuvel.com
- Phone number
- 61 3 9660 4900
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $50K+
- Founded
- 2001-01-01
Headquarters
- Headquarters
- Melbourne, Victoria, Australia
- Postal code
- 3000
- Country code
- AU
- Continent
- Oceania